Breaking News


GenMark Diagnostics to Present at the 31st Annual J.P. Morgan Healthcare Conference

  GenMark Diagnostics to Present at the 31st Annual J.P. Morgan Healthcare

Business Wire

CARLSBAD, Calif. -- January 4, 2013

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated,
multiplex molecular diagnostic testing systems, will present at the 31^st
Annual J.P. Morgan Healthcare Conference to be held at the Westin St. Francis
Hotel in San Francisco on January 8, 2013. Hany Massarany, President and Chief
Executive Officer, will present at 11:30 a.m. Pacific time (2:30 p.m. Eastern
time) with a question and answer session scheduled immediately following the


GenMark Diagnostics is a leading provider of automated, multiplex molecular
diagnostic testing systems that detect and measure DNA and RNA targets to
diagnose disease and optimize patient treatment. Utilizing GenMark's
proprietary eSensor® detection technology, GenMark's eSensor XT-8™ system is
designed to support a broad range of molecular diagnostic tests with a
compact, easy-to-use workstation and self-contained, disposable test
cartridges. GenMark currently markets four tests that are FDA cleared for IVD
use: Cystic Fibrosis Genotyping Test, Respiratory Viral Panel, Thrombophilia
Risk Test, and Warfarin Sensitivity Test. A number of other tests, including
HCV Genotyping, 2C19 Genotyping, and 3A4/3A5 Genotyping are in development.
For more information, visit


This press release includes forward-looking statements regarding events,
trends, and business prospects, which may affect our future operating results
and financial position. Such statements including, but not limited to, those
regarding our growth strategy, are all subject to risks and uncertainties that
could cause our actual results and financial position to differ materially
from those expressed or implied by such statements. Some of these risks and
uncertainties include, but are not limited to, our research and development
plans and timelines, including those with respect to our NexGen platform,
risks related to our history of operating losses, the need for further
financing and our ability to access the necessary additional capital for our
business, inherent risk and uncertainty in the protection of our intellectual
property rights, and regulatory uncertainties regarding approval or clearance
for our products, as well as other risks and uncertainties described under the
"Risk Factors" in our public filings with the Securities and Exchange
Commission. We assume no responsibility to update or revise any
forward-looking statements to reflect events, trends or circumstances after
the date they are made.


GenMark Diagnostics, Inc.
Hany Massarany
President, Chief Executive Officer
Press spacebar to pause and continue. Press esc to stop.